{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-001711","form_type":"8-K","ticker":"GANX","cik":"0001819411","company_name":"Gain Therapeutics, Inc.","filed_at":"2025-01-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.050025+00:00","generated_at":"2026-05-28T08:54:59.470869+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Gain Therapeutics appoints Gene Mack as permanent CEO, Fuggetta as Principal Financial Officer","bullets":["Gene Mack, interim CEO since June 2024, appointed President and CEO and Board member effective Jan 6, 2025.","Mack resigns as CFO; receives $500K base salary, 50% target bonus, and option for 271,325 shares at $2.44.","Gianluca Fuggetta, VP of Finance, becomes SVP Finance and Principal Financial Officer; base salary CHF 200K.","Mack brings 25+ years biotech experience; Fuggetta previously served as interim Principal Financial Officer in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-001711","json":"https://secwatch.observer/filing/0001104659-25-001711.json","markdown":"https://secwatch.observer/filing/0001104659-25-001711.md","text":"https://secwatch.observer/filing/0001104659-25-001711.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819411/000110465925001711/0001104659-25-001711-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819411/000110465925001711/tm252048d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T08:54:59.470869+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7c7e25a2c8","claim":"Gene Mack was appointed as President and Chief Executive Officer at Gain Therapeutics, Inc..","evidence_excerpt":"announced that Gene Mack has been appointed the Company’s President and Chief Executive Officer and a member of the Company’s board of directors (the “Board of Directors”), effective January 6, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819411/000110465925001711/0001104659-25-001711-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}